


{"id":43385,"date":"2020-09-30T10:52:33","date_gmt":"2020-09-30T08:52:33","guid":{"rendered":"https:\/\/newserver.fyb.de\/chr-hansen-holding-a-s-acquires-jennewein-biotechnology\/"},"modified":"2020-09-30T10:52:33","modified_gmt":"2020-09-30T08:52:33","slug":"chr-hansen-holding-a-s-acquires-jennewein-biotechnology","status":"publish","type":"post","link":"https:\/\/www.fyb.de\/en\/chr-hansen-holding-a-s-acquires-jennewein-biotechnology\/","title":{"rendered":"Chr. Hansen Holding A\/S acquires Jennewein Biotechnology"},"content":{"rendered":"<p>Frank\u00adfurt am Main \u2014 Baker McKen\u00adzie advi\u00adsed Chr. Hansen Holding A\/S (Chr. Hansen) in connec\u00adtion with the acqui\u00adsi\u00adtion of all shares in Jenne\u00adwein Biotech\u00adno\u00adlo\u00adgie GmbH (Jenne\u00adwein), a leading company in the market for human milk oligos\u00adac\u00adcha\u00adri\u00addes (HMOs). The purchase price amounts to appro\u00adxi\u00adm\u00adately EUR 310 million (on a debt-free basis). The tran\u00adsac\u00adtion is expec\u00adted to close before the end of Septem\u00adber&nbsp;2020.<\/p>\n<p>Follo\u00adwing the acqui\u00adsi\u00adtion, Chr. Hansen plans to invest more than EUR 200 million by 2025, inclu\u00adding in a new produc\u00adtion faci\u00adlity. This is inten\u00added to expand HMO capa\u00adcity to meet anti\u00adci\u00adpa\u00adted demand.<\/p>\n<p>Jenne\u00adwein is a leading inter\u00adna\u00adtio\u00adnal biotech\u00adno\u00adlogy company with a range of products in the field of human milk oligos\u00adac\u00adcha\u00adri\u00addes (HMOs) and rare monosac\u00adcha\u00adri\u00addes such as L\u2011fucose and sialic acid. Jenne\u00adwein produ\u00adces a broad port\u00adfo\u00adlio of inno\u00adva\u00adtive HMO products, inclu\u00adding 2\u2032-fucosyllactose, 3\u2032-fucosyllactose, lacto-N-neote\u00adtra\u00adose, and lacto-Ntetra\u00adose. These are rare sugars used in the food indus\u00adtry (espe\u00adci\u00adally in infant milk formula), in the phar\u00admaceu\u00adti\u00adcal indus\u00adtry and in the cosme\u00adtics industry.<\/p>\n<p>Chr. Hansen is a leading global life science company deve\u00adlo\u00adping products based on natu\u00adral ingre\u00addi\u00adents for the food, nutri\u00adtion, phar\u00admaceu\u00adti\u00adcal and agri\u00adcul\u00adtu\u00adral indus\u00adtries. This includes the deve\u00adlo\u00adp\u00adment and produc\u00adtion of cultures, enzy\u00admes, probio\u00adtics and natu\u00adral colors for a variety of foods, confec\u00adtion\u00adery, bever\u00ada\u00adges, dietary supple\u00adments as well as animal feed and crop protec\u00adtion products. This allows food manu\u00adfac\u00adtu\u00adr\u00aders, for exam\u00adple, to reduce the use of chemi\u00adcals and other arti\u00adfi\u00adcial substi\u00adtu\u00adtes, thus crea\u00adting \u201cmore\u201d from \u201cless,\u201d which is what makes the food products in ques\u00adtion special in today\u2019s world. In 2019, Chr. Hansen was ranked the most sustainable company in the world by Corpo\u00adrate Knights.<\/p>\n<p><strong>Advi\u00adsor Chr. Hansen Holding A\/S:<\/strong> <strong>Baker McKen\u00adzie<br>\n<\/strong>Lead Corporate\/M&amp;A: <strong>Chris\u00adtian Atzler, Foto (Part\u00adner, Frankfurt)<br>\n<\/strong>Team: Corporate\/M&amp;A: Dr. Peter Wand (Part\u00adner, Frank\u00adfurt), Dr. Markus M\u00f6rtel (Senior Asso\u00adciate, Frank\u00adfurt), Jessica K\u00f6hler (Asso\u00adciate, Frank\u00adfurt), Rouven Reuter (Asso\u00adciate, Frank\u00adfurt), Esther Xiang (Asso\u00adciate, Frankfurt)<br>\nCommer\u00adcial: Dr. Johan\u00adnes Teich\u00admann (Part\u00adner, Frank\u00adfurt), Dr. Ingmar Oltmanns (Asso\u00adciate, Frank\u00adfurt) Rebecca Romig, Isabel Weaver (both Asso\u00adcia\u00adtes, Frankfurt)<br>\nIP: Dr. Rembert Niebel (Part\u00adner, Frank\u00adfurt), Alex\u00adan\u00adder Ritter (Senior Asso\u00adciate, Munich), Lena Weber (Asso\u00adciate, Frankfurt)<br>\nIT: Dr. Holger Lutz (Part\u00adner, Frank\u00adfurt), Dr. Tobias Born (Senior Asso\u00adciate, Frankfurt)<br>\nRegu\u00adla\u00adtory: Dr. Frank Pfl\u00fc\u00adger (Part\u00adner, Frank\u00adfurt), Dr. Chris\u00adtian Lebrecht (Asso\u00adciate, Frankfurt)<br>\nEmploy\u00adment: Dr. Chris\u00adtian Reichel (Part\u00adner, Frank\u00adfurt), Dr. Felix Diehl (Asso\u00adciate, Frankfurt)<br>\nReal Estate: Dr. Florian Thamm (Part\u00adner, Frank\u00adfurt), Till Pflug (Asso\u00adciate, Frankfurt)<br>\nBanking &amp; Finance: Dr. Oliver Socher (Part\u00adner, Frank\u00adfurt), Silke Fritz (Coun\u00adsel, Frank\u00adfurt), Phil\u00adipp Thimm (Asso\u00adciate, Frankfurt)<br>\nForeign Trade Law: Anahita Thoms (Part\u00adner, D\u00fcssel\u00addorf), Alex\u00adan\u00adder Ehrle (Asso\u00adciate, Berlin)<br>\nAnti\u00adtrust: Gavin Bushell (Part\u00adner, Brussels), Chris\u00adtian Horst\u00adkotte (Part\u00adner, D\u00fcsseldorf)<\/p>\n<p>Inhouse Legal Chr. Hansen: Chris\u00adtel May-Worre (H\u00f8rs\u00adholm, Denmark)<\/p>\n<p><strong>About Baker McKenzie<\/strong><br>\nBaker McKen\u00adzie\u2019s global Corporate\/M&amp;A team advi\u00adses on more cross-border tran\u00adsac\u00adtions than any other law firm. Most recently, Baker McKen\u00adzie advi\u00adsed GEA on the sale of compres\u00adsor manu\u00adfac\u00adtu\u00adrer Bock to NORD, DBAG on an invest\u00adment in conga\u00adtec Holding AG, benpac holding ag on the acqui\u00adsi\u00adtion of Gallus Group, SAP on the sale of the SAP Digi\u00adtal Inter\u00adcon\u00adnect commu\u00adni\u00adca\u00adti\u00adons unit to Sinch AB, Para\u00adgon Part\u00adners on the acqui\u00adsi\u00adtion of Casto\u00adlin Eutec\u00adtic, Air Liquide on the sale of the Sch\u00fclke Group to Swedish finan\u00adcial inves\u00adtor EQT, METRO AG on the sale of its China busi\u00adness and the estab\u00adlish\u00adment of a stra\u00adte\u00adgic part\u00adner\u00adship with Wumei, Bayer AG on the sale of its majo\u00adrity stake in chemi\u00adcal park opera\u00adtor Currenta, SPIE on the acqui\u00adsi\u00adtion of OSMO, Toppan Prin\u00adting Co. Ltd. on its acqui\u00adsi\u00adtion of the German Inter\u00adprint Group, and Evonik on the sale of its methacry\u00adla\u00adtes group to Advent International.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Frank\u00adfurt am Main \u2014 Baker McKen\u00adzie advi\u00adsed Chr. Hansen Holding A\/S (Chr. Hansen) in connec\u00adtion with the acqui\u00adsi\u00adtion of all shares in Jenne\u00adwein Biotech\u00adno\u00adlo\u00adgie GmbH (Jenne\u00adwein), a leading company in the market for human milk oligos\u00adac\u00adcha\u00adri\u00addes (HMOs). The purchase price amounts to appro\u00adxi\u00adm\u00adately EUR 310 million (on a debt-free basis). The tran\u00adsac\u00adtion is expec\u00adted&nbsp;to&nbsp;[\u2026]<\/p>\n","protected":false},"author":2,"featured_media":35274,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"wp_typography_post_enhancements_disabled":false,"footnotes":""},"categories":[886,1364,1366,1367,1368],"tags":[],"class_list":["post-43385","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-general-en","category-featured-en","category-news-en","category-lawyers-tax-advisors-auditors-en","category-lawyers-tax-consultants-auditors","news-category-deals-news-en"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Chr. Hansen Holding A\/S acquires Jennewein Biotechnology - FYB Financial Yearbook<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.fyb.de\/en\/chr-hansen-holding-a-s-acquires-jennewein-biotechnology\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Chr. Hansen Holding A\/S acquires Jennewein Biotechnology - FYB Financial Yearbook\" \/>\n<meta property=\"og:description\" content=\"Frank\u00adfurt am Main \u2014 Baker McKen\u00adzie advi\u00adsed Chr. Hansen Holding A\/S (Chr. Hansen) in connec\u00adtion with the acqui\u00adsi\u00adtion of all shares in Jenne\u00adwein Biotech\u00adno\u00adlo\u00adgie GmbH (Jenne\u00adwein), a leading company in the market for human milk oligos\u00adac\u00adcha\u00adri\u00addes (HMOs). The purchase price amounts to appro\u00adxi\u00adm\u00adately EUR 310 million (on a debt-free basis). The tran\u00adsac\u00adtion is expec\u00adted to [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.fyb.de\/en\/chr-hansen-holding-a-s-acquires-jennewein-biotechnology\/\" \/>\n<meta property=\"og:site_name\" content=\"FYB Financial Yearbook\" \/>\n<meta property=\"article:published_time\" content=\"2020-09-30T08:52:33+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/09\/a-atzler-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"370\" \/>\n\t<meta property=\"og:image:height\" content=\"512\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Tatjana Anderer\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Tatjana Anderer\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.fyb.de\/en\/chr-hansen-holding-a-s-acquires-jennewein-biotechnology\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.fyb.de\/en\/chr-hansen-holding-a-s-acquires-jennewein-biotechnology\/\"},\"author\":{\"name\":\"Tatjana Anderer\",\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/person\/4308b3086925bc8567ceba3ebd69b4ce\"},\"headline\":\"Chr. Hansen Holding A\/S acquires Jennewein Biotechnology\",\"datePublished\":\"2020-09-30T08:52:33+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.fyb.de\/en\/chr-hansen-holding-a-s-acquires-jennewein-biotechnology\/\"},\"wordCount\":597,\"publisher\":{\"@id\":\"https:\/\/www.fyb.de\/en\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.fyb.de\/en\/chr-hansen-holding-a-s-acquires-jennewein-biotechnology\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/09\/a-atzler-1.jpg\",\"articleSection\":[\"General\",\"Featured\",\"News\",\"Lawyers\/Tax-advisors\/Auditors\",\"Lawyers, tax consultants, auditors\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.fyb.de\/en\/chr-hansen-holding-a-s-acquires-jennewein-biotechnology\/\",\"url\":\"https:\/\/www.fyb.de\/en\/chr-hansen-holding-a-s-acquires-jennewein-biotechnology\/\",\"name\":\"Chr. Hansen Holding A\/S acquires Jennewein Biotechnology - FYB Financial Yearbook\",\"isPartOf\":{\"@id\":\"https:\/\/www.fyb.de\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.fyb.de\/en\/chr-hansen-holding-a-s-acquires-jennewein-biotechnology\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.fyb.de\/en\/chr-hansen-holding-a-s-acquires-jennewein-biotechnology\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/09\/a-atzler-1.jpg\",\"datePublished\":\"2020-09-30T08:52:33+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.fyb.de\/en\/chr-hansen-holding-a-s-acquires-jennewein-biotechnology\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.fyb.de\/en\/chr-hansen-holding-a-s-acquires-jennewein-biotechnology\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.fyb.de\/en\/chr-hansen-holding-a-s-acquires-jennewein-biotechnology\/#primaryimage\",\"url\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/09\/a-atzler-1.jpg\",\"contentUrl\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/09\/a-atzler-1.jpg\",\"width\":370,\"height\":512},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.fyb.de\/en\/chr-hansen-holding-a-s-acquires-jennewein-biotechnology\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.fyb.de\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Chr. Hansen Holding A\/S acquires Jennewein Biotechnology\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.fyb.de\/en\/#website\",\"url\":\"https:\/\/www.fyb.de\/en\/\",\"name\":\"FYB Financial Yearbook\",\"description\":\"For Your Business\",\"publisher\":{\"@id\":\"https:\/\/www.fyb.de\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.fyb.de\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.fyb.de\/en\/#organization\",\"name\":\"FYB Financial Yearbook\",\"url\":\"https:\/\/www.fyb.de\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/06\/logo.svg\",\"contentUrl\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/06\/logo.svg\",\"caption\":\"FYB Financial Yearbook\"},\"image\":{\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/person\/4308b3086925bc8567ceba3ebd69b4ce\",\"name\":\"Tatjana Anderer\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/11708a5289b743e6290bae8e4109e97efec1cb1ae5c7065f0bfc5c36f28c7757?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/11708a5289b743e6290bae8e4109e97efec1cb1ae5c7065f0bfc5c36f28c7757?s=96&d=mm&r=g\",\"caption\":\"Tatjana Anderer\"},\"description\":\"Gr\u00fcnderin des FYB-Verlag\",\"sameAs\":[\"http:\/\/neu.fyb.de\"],\"url\":\"https:\/\/www.fyb.de\/en\/author\/tanderer\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Chr. Hansen Holding A\/S acquires Jennewein Biotechnology - FYB Financial Yearbook","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.fyb.de\/en\/chr-hansen-holding-a-s-acquires-jennewein-biotechnology\/","og_locale":"en_US","og_type":"article","og_title":"Chr. Hansen Holding A\/S acquires Jennewein Biotechnology - FYB Financial Yearbook","og_description":"Frank\u00adfurt am Main \u2014 Baker McKen\u00adzie advi\u00adsed Chr. Hansen Holding A\/S (Chr. Hansen) in connec\u00adtion with the acqui\u00adsi\u00adtion of all shares in Jenne\u00adwein Biotech\u00adno\u00adlo\u00adgie GmbH (Jenne\u00adwein), a leading company in the market for human milk oligos\u00adac\u00adcha\u00adri\u00addes (HMOs). The purchase price amounts to appro\u00adxi\u00adm\u00adately EUR 310 million (on a debt-free basis). The tran\u00adsac\u00adtion is expec\u00adted to [&hellip;]","og_url":"https:\/\/www.fyb.de\/en\/chr-hansen-holding-a-s-acquires-jennewein-biotechnology\/","og_site_name":"FYB Financial Yearbook","article_published_time":"2020-09-30T08:52:33+00:00","og_image":[{"width":370,"height":512,"url":"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/09\/a-atzler-1.jpg","type":"image\/jpeg"}],"author":"Tatjana Anderer","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Tatjana Anderer","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.fyb.de\/en\/chr-hansen-holding-a-s-acquires-jennewein-biotechnology\/#article","isPartOf":{"@id":"https:\/\/www.fyb.de\/en\/chr-hansen-holding-a-s-acquires-jennewein-biotechnology\/"},"author":{"name":"Tatjana Anderer","@id":"https:\/\/www.fyb.de\/en\/#\/schema\/person\/4308b3086925bc8567ceba3ebd69b4ce"},"headline":"Chr. Hansen Holding A\/S acquires Jennewein Biotechnology","datePublished":"2020-09-30T08:52:33+00:00","mainEntityOfPage":{"@id":"https:\/\/www.fyb.de\/en\/chr-hansen-holding-a-s-acquires-jennewein-biotechnology\/"},"wordCount":597,"publisher":{"@id":"https:\/\/www.fyb.de\/en\/#organization"},"image":{"@id":"https:\/\/www.fyb.de\/en\/chr-hansen-holding-a-s-acquires-jennewein-biotechnology\/#primaryimage"},"thumbnailUrl":"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/09\/a-atzler-1.jpg","articleSection":["General","Featured","News","Lawyers\/Tax-advisors\/Auditors","Lawyers, tax consultants, auditors"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.fyb.de\/en\/chr-hansen-holding-a-s-acquires-jennewein-biotechnology\/","url":"https:\/\/www.fyb.de\/en\/chr-hansen-holding-a-s-acquires-jennewein-biotechnology\/","name":"Chr. Hansen Holding A\/S acquires Jennewein Biotechnology - FYB Financial Yearbook","isPartOf":{"@id":"https:\/\/www.fyb.de\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.fyb.de\/en\/chr-hansen-holding-a-s-acquires-jennewein-biotechnology\/#primaryimage"},"image":{"@id":"https:\/\/www.fyb.de\/en\/chr-hansen-holding-a-s-acquires-jennewein-biotechnology\/#primaryimage"},"thumbnailUrl":"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/09\/a-atzler-1.jpg","datePublished":"2020-09-30T08:52:33+00:00","breadcrumb":{"@id":"https:\/\/www.fyb.de\/en\/chr-hansen-holding-a-s-acquires-jennewein-biotechnology\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.fyb.de\/en\/chr-hansen-holding-a-s-acquires-jennewein-biotechnology\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.fyb.de\/en\/chr-hansen-holding-a-s-acquires-jennewein-biotechnology\/#primaryimage","url":"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/09\/a-atzler-1.jpg","contentUrl":"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/09\/a-atzler-1.jpg","width":370,"height":512},{"@type":"BreadcrumbList","@id":"https:\/\/www.fyb.de\/en\/chr-hansen-holding-a-s-acquires-jennewein-biotechnology\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.fyb.de\/en\/"},{"@type":"ListItem","position":2,"name":"Chr. Hansen Holding A\/S acquires Jennewein Biotechnology"}]},{"@type":"WebSite","@id":"https:\/\/www.fyb.de\/en\/#website","url":"https:\/\/www.fyb.de\/en\/","name":"FYB Financial Yearbook","description":"For Your Business","publisher":{"@id":"https:\/\/www.fyb.de\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.fyb.de\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.fyb.de\/en\/#organization","name":"FYB Financial Yearbook","url":"https:\/\/www.fyb.de\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.fyb.de\/en\/#\/schema\/logo\/image\/","url":"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/06\/logo.svg","contentUrl":"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/06\/logo.svg","caption":"FYB Financial Yearbook"},"image":{"@id":"https:\/\/www.fyb.de\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.fyb.de\/en\/#\/schema\/person\/4308b3086925bc8567ceba3ebd69b4ce","name":"Tatjana Anderer","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.fyb.de\/en\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/11708a5289b743e6290bae8e4109e97efec1cb1ae5c7065f0bfc5c36f28c7757?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/11708a5289b743e6290bae8e4109e97efec1cb1ae5c7065f0bfc5c36f28c7757?s=96&d=mm&r=g","caption":"Tatjana Anderer"},"description":"Gr\u00fcnderin des FYB-Verlag","sameAs":["http:\/\/neu.fyb.de"],"url":"https:\/\/www.fyb.de\/en\/author\/tanderer\/"}]}},"_links":{"self":[{"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/posts\/43385","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/comments?post=43385"}],"version-history":[{"count":0,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/posts\/43385\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/media\/35274"}],"wp:attachment":[{"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/media?parent=43385"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/categories?post=43385"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/tags?post=43385"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}